Drug Type Monoclonal antibody |
Synonyms JS 003, JS-003 |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 2 | CN | 23 Jan 2024 | |
Non-Small Cell Lung Cancer | Phase 1 | CN | 09 Oct 2017 | |
Kidney Neoplasms | Phase 1 | CN | 21 Mar 2017 | |
Melanoma | Phase 1 | CN | 21 Mar 2017 | |
Advanced Triple-Negative Breast Carcinoma | Phase 1 | CN | 19 Dec 2016 | |
Advanced cancer | Phase 1 | CN | 25 Apr 2016 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 07 Mar 2016 |